AV GBM immunotherapy promising?…

MedMaven

Nov 14, 2019

AV GBM immunotherapy promising?

AIVITA Biomedical Announces New Positive Phase 2 Glioblastoma Data at SITC Annual Meeting Podium Presentation

IRVINE, Calif. – November 12, 2019 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that data from its ongoing Phase 2 clinical trial in GBM was presented at the Society for Immunotherapy of Cancer Annual Meeting by Principal Investigator Dr. Daniela Bota. The oral presentation was titled “Phase

Comments (2)

No. 1-2

MedMaven

Editor

Mar 19

Gene therapy promising for recurrent GBM: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noz231/5679561

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study

AbstractBackground. VB-111 is a non-replicating adenovirus carrying a Fas-chimera transgene, leading to targeted apoptosis of tumor vascular endothelium and in

MedMaven

Editor

Jan 28

Harvard doctors also pioneering a promising immune approach:

Neoantigen vaccine spurs immune response in glioblastoma - Dana-Farber Cancer Institute | Boston, MA

In a report published in Nature, however, scientists at Dana-Farber Cancer Institute say they have shown that a personalized ‘neoantigen’ vaccine can spur a response against glioblastoma, with immune T-cells generated by the vaccine migrating into the brain tumor, creating a ‘hotter,’ inflamed environment around the cancer cells.